

**Louisiana Department of Health
Medicaid Pharmaceutical and Therapeutics Committee
TOP\$ Virtual Review
Via Videoconferencing
May 7, 2021
9:00 AM
DRAFT**

- I. Call to Order.....Marty McKay
- II. Parliamentary BusinessMarty McKay
 - A. Introduction of Members/Roll Call
 - B. Attendance/Additional Meetings
- III. P & T Committee Review Virtual Process.....Hind Douiki/Melwyn Wendt
- IV. Reports.....Melwyn Wendt
 - A. Prior Authorization Monthly Report
 - B. PDL Reflecting Fall 2021 Recommendations
 - C. Louisiana Medicaid Preferred Drug List Program Overview and Results Report – December 16, 2020
- V. New Business.....Hind Douiki
 - A. Explanation of TOP\$, Monographs and Cost Sheets
 - B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
 - 1. Acne Agents, Topical
 - 2. Analgesics, Narcotics Long
 - 3. Analgesics, Narcotics Short
 - 4. Androgenic Agents
 - 5. Angiotensin Modulator Combinations
 - 6. Angiotensin Modulators
 - 7. Antibiotics, GI
 - 8. Antibiotics, Inhaled
 - 9. Antibiotics, Topical
 - 10. Antibiotics, Vaginal
 - 11. Anticoagulants
 - 12. Antiemetic/Antivertigo Agents
 - 13. Antifungals, Oral
 - 14. Antifungals, Topical
 - 15. Antimigraine Agents, Other
 - 16. Antimigraine Agents, Triptans
 - 17. Antiparasitics, Topical
 - 18. Antivirals, Oral
 - 19. Antivirals, Topical
 - 20. Beta-Blockers
 - 21. Bladder Relaxant Preparations
 - 22. Bone Resorption Suppression and Related Agents

23. BPH Treatments
24. Calcium Channel Blockers
25. Cephalosporins and Related Antibiotics
26. Cystic Fibrosis, Oral
27. Fluoroquinolones, Oral
28. GI Motility, Chronic
29. Glucagon Agents – New
30. Growth Factors - New
31. Growth Hormone
32. H. Pylori Treatment
33. HAE Treatments – New
34. HIV / AIDS - New
35. Hypoglycemics, Alpha-Glucosidase Inhibitors
36. Hypoglycemics, Incretin Mimetics/Enhancers
37. Hypoglycemics, Insulin and Related Agents
38. Hypoglycemics, Meglitinides
39. Hypoglycemics, Metformins
40. Hypoglycemics, SGLT2
41. Hypoglycemics, Sulfonylureas
42. Hypoglycemics, TZD
43. Immunosuppressives, Oral
44. Lincosamides/Oxazolidinones/Streptogramins
45. Lipotropics, Other
46. Lipotropics, Statins
47. Macrolides/Ketolides
48. Multiple Sclerosis Agents
49. Nitrofurans Derivatives
50. Opiate Dependence Treatments
51. PAH Agents, Oral and Inhaled
52. Pancreatic Enzymes
53. Pediatric Vitamin Preparations
54. Phosphate Binders
55. Pituitary Suppressive Agents, LHRH
56. Platelet Aggregation Inhibitors
57. Pleuromutilins – New
58. Potassium Binders - New
59. Proton Pump Inhibitors
60. Sinus Node Inhibitors
61. Skeletal Muscle Relaxants
62. Tetracyclines
63. Ulcerative Colitis Agents
64. Uterine Disorder Treatments
65. Vasodilators, Coronary

C. Hepatitis C Agents

VI. New & Other Single Drug Reviews.....Hind Douiki

- 66. Antipsoriatics, Topical – Wyzora[®]
- 67. Anticonvulsants – Felbatol[®] Suspension (Oral)
- 68. Anticonvulsants - Felbamate Suspension (Oral)
- 69. Colony Stimulating Factors – Nyvepria[®] (Subcutaneous)
- 70. Cytokine and CAM Antagonists – Xeljanz[®] Solution (Oral)
- 71. Glucocorticoids, Oral – Alkindi[®] Sprinkle
- 72. Hemophilia Treatment – Sevenfact[®] (Intraven)
- 73. Methotrexate – Reditrex[®] Syringe (Subcutaneous)
- 74. NSAIDS - Ibupak[®] Kit (Oral)
- 75. NSAIDS – Venngel[®] One Kit (Topical)
- 76. Oncology, Oral – Lung - Tepmetko[®] (Oral)
- 77. Oncology, Oral – Prostate - Orgovyx[®] (Oral)
- 78. Ophthalmics, Anti-Inflammatory/Immunomodulator – Eysuis[®]
- 79. Sedative Hypnotics – Hetlioz LQ[®] (Oral)
- 80. Steroids, Topical, Very High – Impeklo[®] Lotion
- 81. Steroids, Topical, Very High – Clobetavix[®] Kit

VII. Other Business

VIII. Next Steps

- A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – Wednesday, October/November 2021

X. Public Testimony